Patent ID: 7901698

Claim:
A topically applicable pharmaceutical composition for use in the treatment of psoriasis, consisting essentially of: (a) cyclomethicone 5/dimethicone crosspolymer, in an amount of from 74.9347 to about 78.9347% by weight relative to the total weight of the composition; (b) calcitriol, in an amount of 0.0003% by weight relative to the total weight of the composition; (c) clobetasol 17-propionate, in an amount of 0.025% by weight relative to the total weight of the composition; (d) at least two solvents in which (b) and (c) are solubilized which are at least absolute ethanol and cyclopentasiloxane; (e) an oily additive selected from the group consisting of isopropyl palmitate, dicapryl ether and dimethicone; and (f) butylated hydroxytoluene; said composition having a zero water content and being physically stable for at least one month at 4° C. and 40° C.